A new recombinant virus system for the study of HIV-1 entry and inhibition.
The construction is described of a HIV-1 proviral, eGFP-tagged plasmid that allows for the recombination of any selected env gene without the use of restriction enzymes and for the quantitation of the infection by the recombinant virus using flow cytometry. The system was tested showing that an isoleucine to valine substitution at residue position 37 of the HIV-1 gp41 impairs the fitness of the virus but does not lead by itself to T-20 resistance.
Roman
Francois
F
Retrovirology Laboratory, Centre de Recherche-Public (CRP)-Santé, 84 rue Val Fleuri, L-1526 Luxembourg, Luxembourg. roman.f@retrovirology.lu
Ammerlaan
Wim
W
Plesseria
Jean-Marc
JM
Deroo
Sabrina
S
Muller
Claude P
CP
Arendt
Vic
V
Schneider
Francois
F
Hemmer
Robert
R
Schmit
Jean-Claude
JC
D019943:Amino Acid Substitution; D003001:Cloning, Molecular; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D005434:Flow Cytometry; D015700:HIV Envelope Protein gp41 / Q000235:genetics / Q000494:pharmacology; D023581:HIV Fusion Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D010446:Peptide Fragments / Q000494:pharmacology; D011533:Proviruses / Q000187:drug effects / Q000235:genetics* / Q000502:physiology; D014779:Virus Replication
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide